0.39
-0.1143(-22.49%)
Currency In USD
| Previous Close | 0.51 |
| Open | 0.43 |
| Day High | 0.5 |
| Day Low | 0.25 |
| 52-Week High | 1.94 |
| 52-Week Low | 0.25 |
| Volume | 4.01M |
| Average Volume | 2.99M |
| Market Cap | 9.91M |
| PE | -0.43 |
| EPS | -0.91 |
| Moving Average 50 Days | 0.47 |
| Moving Average 200 Days | 0.54 |
| Change | -0.11 |
If you invested $1000 in Sensei Biotherapeutics, Inc. (SNSE) since IPO date, it would be worth $20.85 as of April 01, 2025 at a share price of $0.394. Whereas If you bought $1000 worth of Sensei Biotherapeutics, Inc. (SNSE) shares 3 years ago, it would be worth $175.11 as of April 01, 2025 at a share price of $0.394.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
GlobeNewswire Inc.
Mar 27, 2025 8:05 PM GMT
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patie
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 04, 2025 12:30 PM GMT
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Ce
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
GlobeNewswire Inc.
Jan 08, 2025 12:30 PM GMT
- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage b